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ABSTRACT
The transdermal drug delivery system is widely accepted due to its numerous advantages as it is a non-invasive drug administration process with 
prolonged therapeutic effect, reduced side effects, improved bioavailability, better patient compliance, and easy termination of drug therapy. Non-
steroidal anti-inflammatory drugs such as Diclofenac sodium, Lornoxicam, Aceclofenac, Ibuprofen, antihypertensive drugs, for example, Repaglinide, 
Atenolol, and Antiviral agents such as Stavudine, zidovudine represents the most commonly used medications for the treatment of pain and 
inflammatory reaction but various side effects can limit their use. Therefore, transdermal delivery of these drugs has advantages of avoiding hepatic 
first-pass effect, gastric irritation and delivering the drug for an extended period of time at a sustained level. The present article mainly focuses on the 
work been done on these drugs by formulated and delivered as transdermal patches to decrease the side effects related to the oral delivery.
Keywords: Transdermal patch, Non-steroidal anti-inflammatory drugs, Repaglinide, Diclofenac sodium, Inflammation.
INTRODUCTION
Inflammation
Inflammation is a process that occurs after an infection or tissue injury. 
The inflammatory response is essential in maintaining homeostasis 
which leads to tissue damage due to fibroplasia, leukocytosis, excessive 
production of cytokines and other mediators such as tumor necrosis 
factor-α-alpha, interleukin (IL)-6, and IL-8. Inflammation is also 
an important physical factor that triggers the immune reaction [1]. 
Superficial pain arises from nociceptive receptors in the skin and mucous 
membranes and is often associated with inflammation and tissue 
swelling [2]. In general, non-steroidal anti-inflammatory drugs (NSAIDs) 
can be used for the treatment of pain and inflammation. The NSAIDs can 
inhibit the activity of cyclooxygenase enzymes (COX-1 and COX-2) and 
therefore inhibit the synthesis of thromboxanes and prostaglandins 
(PGE2) [3]. COX enzyme is released during pain and inflammation, 
whereas thromboxanes and PGE2 are considered as the mediators 
of allergic reactions such as vasoconstriction and inflammation. [4]. 
Example of some commonly used NSAIDs includes aspirin, ibuprofen, 
naproxen and diclofenac. Diclofenac is used for the treatment of mild 
to moderate muscular pain and to alleviate the symptoms of arthritis, 
menstrual cramps, toothache and migraines/headaches [5]. However, if 
it is taken orally for a long period of time in high doses then it may lead to 
fatal stomach, intestinal bleeding and heart attack or stroke [6].
As an alternative to oral drug delivery and parenteral administration for 
NSAIDs, now a days Transdermal drug delivery (TDD) is mostly preferred 
reasons [7]. Among the various advantages, one advantage is that the 
transdermal route avoids the metabolism of the drug inside the liver and 
its rapid absorption inside the gastrointestinal (GI) tract, thus avoiding 
the risk of internal bleeding and irritation. In the TDD systems, drugs are 
specifically designed to deliver a predestined amount of drug through 
the stratum corneum and the systemic circulation [8]. The choice of drug 
for TDD depends on the size of the drug, as it can pass through the skin 
pores. However, improper use of the strong ointments can potentially 
lead to skin allergies, dryness, lesions, and thinning of the skin [9].
In TDDS systems mostly drug-loaded patches, backing films, 
microneedles, thermal, mechanical and electrical ablation, are often 
preferred [10]. For treatment of muscular pain, a few transdermal 
patches are available on the market and these are mostly based on either 
narcotic (Fentanyl) or methyl salicylate (Salonpas), which can cause 
breathing problems, or toxicity issues [11,12]. TDD system allows the 
administration of potent drugs with the benefit of self–administration 
and enhanced therapeutic efficacy [13].
It is caused by injury to the living tissue. It involves the 4 primary 
indicators of inflammation that is pain, redness, heat, swelling. The role 
of inflammation such as healing, restorative process and also having an 
aggressive role, which is more widely recognized [14].
Inflammation is a programmed local tissue response
↓
Peculiar to vascularized living tissue
The inflammatory response involves different events which can be 
elicited by numerous stimuli, for example, chemical, thermal injury and 
antigen-antibody interactions. The different events of inflammation are 
underlined different manifestations that is induced and regulated by a 
large number of chemical mediators, eicosanoids, kinins, etc. [14]. The 
main aim of inflammatory response is to localize and eliminates the 
harmful agents; secondly remove the damaged tissue components to 
culminate in the healing of the affected tissues [15].
THE INFLAMMATORY RESPONSE
PGE2 has various physiological roles including regulation of normal 
body temperature, renal blood flow, gastric mucosal integrity, etc. The 
pathway of PGs synthesis starts with the generation of arachidonic acid 
from cell membrane phospholipid by PLA2. Then, arachidonic acid 
is converted to PGs by the enzyme COX. Mostly the inducible enzyme 
COX-2 is acting as the most active during inflammatory processes. LTs 
are produced by the enzyme 5-lipooxygenase. It is highly associated 
with an inflammatory condition that is nitric oxide synthase which 
produces NO and causes inflammation. According to the WHO, in 2018 
approx 235 million people suffer from inflammation in the world. 
The symptomatic relief provides relief to the patient suffering from 
inflammatory autoimmune diseases (Fig. 1).
Inflammation is classified into two types
•	 Acute inflammation
•	 Chronic inflammation.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Acute inflammation is defined as a rapid response to a harmful agent 
that serves to deliver mediators of host defense, leukocytes, and plasma 
proteins to the site of injury. It gives an initial response of the body to 
harmful stimuli [16].
ACUTE INFLAMMATION HAS 3 MAJOR COMPONENTS
•	 Alterations in the vascular caliber that lead to an increase in blood 
flow
•	 Structural changes in the microvasculature that permits plasma 
proteins and leukocytes to leave the circulation
•	 Leucocyte emigrates from the microcirculation, their accumulation 
within the focus of injury and their activation to eliminate the 
offending agent.
CHEMICAL MEDIATORS OF ACUTE INFLAMMATION
•	 Histamine: increased permeability
•	 PGE2: vasodilation
•	 Leukotrienes: increased permeability.
Morphology of acute inflammation
•	 Pseudomembranous inflammation
It is an inflammatory response of the mucous surface to toxins of 
diphtheria or irritant gases.
•	 Ulcer
Ulcers are local defects on the surface of an organ produced by 
inflammation.
•	 Cellulitis
Due to the spreading effects of substances such as hyaluronidase released 
by some bacteria, diffuse inflammation of soft tissues can take place [17].
Chronic inflammation can be defined as a prolonged process in which 
tissue destruction and inflammation occur at the same time. In general, 
for chronic inflammation, the extent and effects of inflammation may 
vary with the cause of the injury and the ability of the body to repair and 
overcome the damage. In this inflammation process, the inflammatory 
response is out of a fraction resulting in damage to the body [18]. 
Common symptoms of chronic inflammation are fatigue, fever, mouth 
sores, rashes, abdominal pain, etc. In chronic inflammation, disorders, 
such as arthritis and hemorrhoids, that continued to torment humanity 
despite nature’s endowment of medicinal plant resources (Fig. 2) [19].
GENERAL FEATURES OF CHRONIC INFLAMMATION
•	 Mononuclear cell infiltration: phagocytes, circulating monocytes, 
macrophages, etc.
•	 Tissue destruction or necrosis
•	 Proliferative changes: small blood vessels and fibroblasts.
Nonsteroidal anti-inflammatory drugs are the agents which suppresses 
the inflammation. These agents have also adverse effects such as 
peptic ulceration and osteoporosis [20]. NSAID’S are one of the 
common therapeutic agents used for the treatment of pain, fever, 
and inflammation. Examples: Diclofenac, Ibuprofen, Naproxen, and 
Celecoxib [21].
In this review, we are discussing the different types of the transdermal 
patchs.
TRANSDERMAL PATCH
The Transdermal patch is medicated adhesive patch. These are prepared 
which deliver a therapeutically effective amount of drugs across the 
skin. The patches provide a controlled release of the medication into 
the patient (Fig. 3).
It acts as a carrier for a drug which holding it until the point of 
application. At this point, the adhesive secures the patch to the skin. It 
allows the drug access to the skin, it helps the permeation process. It 
delivers the drugs topically. A transdermal patch containing a high dose 
of drug into the skin which is retained for a prolonged period of time, 
gets entered the blood flow through the diffusion process.
Advantages
1. Self- medication is possible
2. Unwanted side effects get minimized
3. First pass metabolisms of drug get avoided.
Disadvantages
1. Larger molecules size of the drug creates difficulty in absorption
2. Chances of allergic reactions at the site of applications such as itching, 
rashes, etc.
Transdermal drug administration generally refers to the topical 
application which intact in the skin simultaneously minimizes the 
retention and also metabolism of the drug in the skin. TDD systems 
are used in the skin disorders, pains, angina pectoris, neurological 
disorders, etc. TDD systems are considered as the new drug delivery 
systems which involve the demonstration of clinical safety and 
effectiveness of the drug. In novel techniques, drug delivery has 
been investigated in human medicine in recent years. Among the 
new drug delivery systems, there are mostly used for transdermal 
applications [21].
Limitations of TDD systems
•	 It cannot administer drugs that require high blood levels
•	 Drug formulation may cause irritation or sensitization.
Infection Tissue injury Tissue stress and malfunction
Host defense against infection 
Tissue repair response 
Adaption to stress and
restoration of a homeostatic state











Fig. 2: Causes of acute and chronic inflammation
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Components of transdermal patches
The basic components of transdermal patches are consist of a polymer 
matrix, drug reservoir, active ingredient, permeation enhancers, 
backing laminates, adhesives, plasticizers, solvents, etc. [22].




In the 1st generation transdermal patches, it is used in clinics. These are 
consisting of the drug in a reservoir that is enclosed by one side with 
impermeable adhesives. In the 2nd generation, the transdermal patches 
increased the skin permeability which reduces damage to deeper 
tissues. Again In the 3rd generation, the transdermal patches increased 
the skin penetration of drugs which also protect the deeper tissues [22]. 
Transdermal patches are generally provided constant blood levels but 
avoid the first-pass metabolism. It increased patient compliance.
Method of preparation of transdermal patches
•	 Asymmetric TPX membrane method
•	 Circular teflon mould method
•	 EVAC membrane method
•	 Mercury substrate method.
Selection of drug candidate for the transdermal delivery system
The drug candidate should be:
•	 Adequate skin permeability
•	 Adequate skin acceptability
•	 Adequate clinical need.
Examples of transdermal patches
Transdermal patch of diclofenac sodium
It has been investigated that diclofenac sodium patches using chitosan 
and polyvinyl alcohol (PVA) cross-linked tripolyphosphate sodium to 
increased transdermal permeation of the drug from the matrix system 
across rabbit skin.
The investigation of diclofenac sodium patch was done by ultraviolet 
spectrophotometry. Determination of physical characteristics of the 
film includes the weight test, thickness, organoleptic observation, 
interaction between materials used in Fourier transform infrared 
(FTIR). It has been observed that the result of physicochemical 
parameters of the transdermal patches has been found satisfactory. 
The FTIR data of rabbit skin indicated chitosan and PVA alcohol cross-
linked TPP increases transdermal permeation of Diclofenac sodium 
in the stratum corneum [23]. An ideal transdermal patch should 
have flexibility, elasticity, and softness and at the same time must 
have sufficient strength to follow the body contours. It also has good 
adhesive strength for prolonged retention on the skin for the desired 
duration of action. In addition, various permeation enhancers and 
chemicals are used to improve penetration across the skin, including 
alcohols, terpenes, and surfactants [24,25].
Postsurgical pain has often been a nemesis for surgeons and patients 
alike due to a considerable degree of inflammatory response involved. 
NSAIDs are among the most generally utilized medication as because 
they decrease the inflammatory responses [26]. Diclofenac sodium, 
an aryl acetic acid derivative is the regularly utilized NSAID either 
as a sole agent or in combination with different NSAIDs [5]. It is a 
nonselective cox inhibitor (conventional NSAID) that acts by inhibiting 
COX enzyme [27]. A benefit of a transdermal medication over different 
kinds such as oral, skin, and so on, is that it gives a controlled release of 
the medicament into the circulation [11]. The transdermal diclofenac 
patch (Nu Patch) is utilized to relieve postoperative pain. It is applied 
once for the span of 24 h and produces quick relief from discomfort 
with negligible or no side effects. The patch is to be applied on the skin, 
ideally in a space without any hair [28]. The patch achieves plasma 
levels ranging between 20 and 50 ng/ml and it is lesser when compared 
to the oral route [29].
Transdermal gel patch of lornoxicam (LRX)
LRX is a potent NSAID that belongs to oxicam class. It is mainly used 
in chronic pain and inflammatory conditions. It also shows numerous 
GI, renal, and hematological adverse effects when taken orally [30]. 
Frequent administration of LRX is required due to its short half-
life (3–4 h). However, in the case of chronic conditions parenteral 
administration is not recommended [31]. Oleic acid (OA) has been 
widely used for improving percutaneous drug absorption. It has been 
proved that the use of OA with propylene glycol gives satisfactory 
results in many transdermal formulations [24,32,33]. LRX, similar to 
other NSAIDs, decreases the PGE2 synthesis by inhibiting both isoforms 
of the COX enzymes in the same proportions [34]. Inhibition of (PG) 
synthesis help to protect the gastrointestinal mucosal membrane 
by preventing the gastric acid secretion and it also strengthened the 
mucosal barrier for gastric acid. However, the inhibition of PG synthesis 
may cause heartburn, mild dyspepsia, ulceration, and hemorrhage [35].
Sodium alginate is a biopolymer that has been widely used as a 
binding and disintegrating agent in the formulation of tablets [36,37]. 
Sodium alginate has a unique ability to form gel in the presence of 
calcium chloride, and it also delays the dissolution of a drug from 
sustained -release formulations [38]. The permeation enhancers are 
used to facilitate the transdermal delivery of hydrophilic and lipophilic 
medications, for example, dimethyl sulfoxide [39]. The membrane-
based transdermal patches for LRX gel have been studied using OA 
and polypropylene glycol as penetration enhancers to improve the 
drug delivery across the skin and also evaluated the In vivo analgesic 
and anti-inflammatory activity. It has been previously demonstrated 
that the fabricated transdermal gel patch of LRX can deliver the drug 
through the skin in a controlled release manner with desired anti-
inflammatory activity [40].
Transdermal patch of repaglinide
The transdermal patch of repaglinide has been prepared to sustain the 
release and improve the bioavailability of drug and patient compliance. 
The formulations were prepared by solvent casting method. The 
prepared formulations were evaluated for various parameters such 
as tensile strength, %drug content, %moisture content, and folding 
endurance. Repaglinide has the half- life of 1 h, bioavailability in the 
body is 56% due to first-pass metabolism [41]. Diabetes mellitus 
is a chronic metabolic disorder mainly caused by hyperglycemia 
caused by insulin deficiency, and it is often combined with insulin 
Fig. 3: Types of patchs
24
Asian J Pharm Clin Res, Vol 14, Issue 12, 2021, 21-26
 Choudhury et al.
resistance [42]. Repaglinide belongs to meglitinide class of drugs 
used to treat noninsulin-dependent diabetes mellitus. Repaglinide is 
generally given in a dose of 0.5–4 mg (3–4 times) in a day. The melting 
point of Repaglinide is 130–131°C and has mol. wt. of 452.58 [43,44]. 
It has been proved that repaglinide produces hypoglycemia after oral 
administration [45]. The Topical preparation of repaglinide may be 
beneficial to the patient since it reduces adverse effects and avoids the 
hepatic first-pass metabolism [46,47].
Transdermal patch of atenolol
Atenolol is a beta-adrenergic receptor blocking agent used for 
the treatment of hypertension [48,49]. The elimination half -life 
is 6–7 h after oral administration. The absolute bioavailability is 
approximately 50% due to first -pass metabolism [50,51]. The action 
of the sympathetic nervous system is blocked by Atenolol. On the basis 
of that, a transdermal patch has been prepared by using cellulose 
acetate phthalate, polyvinyl pyrrolidine, and polyethylene glycol [52]. 
The purpose of the study was to provide the delivery of the drug 
at a controlled rate across intact skin [53]. It has been reported that 
administration of conventional tablets of atenolol exhibits fluctuations 
in the plasma drug level which results in either manifestation of side 
effects or reduction in drug concentration at the receptor site [54,55]. 
The researchers developed a transdermal delivery system containing 
atenolol and hydrochlorothiazide might be a milestone in the 
combinational therapy of hypertension [56]. The in vivo evaluation of 
formulation (2% Eudragit RS 100, 1%HPMC) has been studied and it 
shows a better correlation with the in-vitro drug release which confirms 
the achievement of targets of the present study such as controlled 
prolonged zero-order release, reduced frequency of administration, 
greater therapeutic effect, overcome the side effects, simplify the 
treatment regimen and thus may improve patient compliance [57]. 
A study of transdermal patch of Atenolol has been carried out to 
develop matrix-based transdermal patches which containing Atenolol. 
The patches were prepared by solvent casting method.
Transdermal patch of Stavudine
The matrix-type TDD systems of Stavudine have been developed using 
hydrophilic and hydrophobic polymers for controlled release, showed 
suitable physicochemical properties. It has been confirmed that 
Stavudine permeated through the rat abdominal skin and hence could 
permeate through the human skin [19,58]. Another study revealed 
that the Transdermal patch of Stavudine has been prepared by using 
different concentrations of Eudragit RS 100 and Eudragit RL 100. These 
Prepared patches were found to have smooth and uniform surfaces 
when they are functional onto the skin [59,60]. It has been proved 
that the transdermal patch of Stavudine improves the bioavailability 
of drugs and patient compliance. These patches were characterized 
by Field Emission Scanning Electron Microscopy. Stavudine has the 
half -life of 1–1.5 h and bioavailability in the body is 86% due to first-
pass metabolism [18].
Transdermal patch of Aceclofenac
ACF inhibited the enzyme COX enzyme. In vitro data revealed that 
the inhibition of Cox-1 and Cox-2 by ACF in whole blood assays, with 
selectivity for Cox-2 being evident [61]. If ACF is used in patients with 
ankylosing spondylitis, it reduces the duration of morning stiffness 
and pain intensity and also improved the spinal mobility [62]. ACF 
is metabolized to a major metabolite, 4’-hydroxy ACF, and various 
metabolites including 5-hydroxy ACF, 4’- hydroxydiclofenac, diclofenac, 
and 5-hydroxydiclofenac [63]. It has been previously described the use 
of hydroxyl propyl cellulose in transdermal patches and ophthalmic 
preparations and ethyl cellulose transdermal delivery systems as well as 
other dosage forms for controlled release of drugs [64-67]. Aceclofenac 
transdermal patch has been prepared by using a combination of HPMC 
and MC. A study was conducted using HPMC and MC (50:50) with 
30% plasticizer and the results showed that it may be suitable for the 
development of TDD systems of Aceclofenac [68,69].
Transdermal patch of Zidovudine
Zidovudine (AZT) is a polar molecule. The diffusion of AZT across stratum 
corneum is poor and below the level to achieve effective therapeutic 
plasma concentration [70]. It has been previously studied that using 
terpenes (anethole) along with polyols such as propylene glycol and 
polyethylene glycol as penetration enhancers could be effective in 
achieving therapeutic plasma levels for AZT [42,71]. Immediately 
after intravenous or oral administration, AZT showed excessive 
plasma level [72]. Therefore, the delivery from a non-oral pathway 
such as the transdermal route may be helpful in maintaining suitable 
plasma concentration and also useful in improving bioavailability and 
patient compliance and in avoiding side effects [73,74]. The benefit of 
transdermal delivery of AZT has been successfully studied [75,76].
Transdermal patch of ibuprofen
Ibuprofen is employed to ease moderate pain, reduce swelling, control 
fever, and treat arthritis at higher doses [77,78]. However, along with 
other NSAIDs, ibuprofen causes (gastritis) which may result in a 
stomach ulcer or even bleeding [79,80]. A novel TEPI® transdermal 
patch technology is reported and is exemplified with ibuprofen as 
the active pharmaceutical ingredient and a new HMPSA cross-linked 
polymer excipient as a drug reservoir [81,82]. The transdermal 
patchs of ibuprofen has been evaluated through it,s organoleptic, 
weight uniformity, drug content, etc. Ibuprofen is an NSAID drug. It 
causes gastric irritation when administered orally. The evaluation and 
formulation of transdermal patch of Ibuprofen have been carried out to 
prevent this side effect [16].
DISCUSSION
In this review article, we provided valuable information regarding the TDD 
systems, transdermal patches, and their physicochemical parameters. 
Furthermore discussed the inflammation, mechanisms of inflammation, 
studied about the anti-inflammatory drugs, types of inflammation, etc.
CONCLUSION
TDD systems have been effective for painless, efficient, non-toxic, and 
patient-compliant drug delivery. The development of an efficient means 
of transdermal administration of NSAIDs may increase local soft tissue 
and joint concentrations and also reduces the side effects associated 
with oral administration. Various NSAID drugs may be incorporated 
for targeting a variety of skin disorders but all NSAIDs cannot be given 
by this route because of their physicochemical properties which are 
essential for the transdermal delivery of drugs. Therefore, the potential 
of this delivery system needs to be explored in the case of NSAIDs. The 
Transdermal patch of Repaglinide improves the bioavailability of drug 
and patient compliance. Stavudine has the ability to permeate through 
the rat abdominal skin and hence could permeate through the human 
skin. Terpenes (anethole) along with propylene glycol and polyethylene 
glycol as penetration enhancers could be effective in achieving 
therapeutic plasma levels for AZT. The Transdermal patch of Atenolol 
provides the delivery of the drug at a controlled rate across intact skin. 
Moreover, the transdermal patch has enormous potential to be used 
not only for the management of inflammatory reactions but also for 
other conditions requiring transdermal drug release. Moreover, the 
transdermal patch has enormous potential to be used not only for the 
management of inflammatory reactions but also for other conditions 
requiring transdermal drug release.
ACKNOWLEDGMENT
The authors would like to acknowledge NETES Institute of 
Pharmaceutical Science, Mirza, Santipur, Assam, for providing their lab 
facilities and library.
AUTHORS’ CONTRIBUTIONS
Manuscript framing and the concept has been presented by Deijy 
Choudhury. Literature search and preparation have been done by Mr. 
25
Asian J Pharm Clin Res, Vol 14, Issue 12, 2021, 21-26
 Choudhury et al.
Ramen Kalita. Reviewing and editing have been done by Mr. Koushik 
Nandan Dutta.
CONFLICT OF INTEREST STATEMENT




1. Chen L, Deng H, Cui H, Fang J, Zuo Z. Inflammatory responses 
and inflammation-associated diseases in organs. Oncotarget 
2018;9:7204-18.
2. Sogaard K, Sjogaard G. Physical activity as cause and cure of muscular 
pain: Evidence of underlying mechanisms. Exerc Sport Sci Rev 
2017;45:136-45.
3. Pascottini OB, Spricigo JF, Van Schyndel SJ, Mion B, Rousseau J, 
Weese JS, et al. Effects of parity, blood progesterone, and non-steroidal 
anti-inflammatory treatment on the dynamics of the uterine microbiota 
of healthy postpartum dairy cows. PLoS One 2021;16:e0233943.
4. Sharma CS, Khandelwal M. A novel transdermal drug-delivery patch 
for treating local muscular pain. Ther Deliv 2018;9:405-7.
5. Diwan V, Srinivasa TS, Ramreddy KY, Agrawal V, Nagdeve S, 
Parvez H. A comparative evaluation of transdermal diclofenac patch 
with oral diclofenac sodium as an analgesic drug following periodontal 
flap surgery: A randomized controlled clinical study. Indian J Dent Res 
2019;30:57-60.
6. Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-
steroidal anti-inflammatory drug-induced cardiovascular adverse 
events: A meta-analysis. J Clin Pharm Ther 2017;42:27-38.
7. Zhang D, Bian Q, Zhou Y, Huang Q, Gao J. The application of label-free 
imaging technologies in transdermal research for deeper mechanism 
revealing. Asian J Pharm Sci 2021;16:265-79.
8. Hua S. Advances in nanoparticulate drug delivery approaches for 
sublingual and buccal administration. Front Pharmacol 2019;10:1-9.
9. Xie Y, Shao R, Lin Y, Wang C, Tan Y, Xie W, et al. Improved therapeutic 
efficiency against obesity through transdermal drug delivery using 
microneedle arrays. Pharmaceutics 2021;13:827.
10. He X, Sun J, Zhuang J, Xu H, Liu Y. Microneedle system for 
transdermal drug and vaccine delivery: Devices, safety, and prospects. 
Dose Response 2019;17:1559325819878585.
11. Pandey PC, Shukla S, Skoog SA, Boehm RD, Narayan RJ. Current 
advancements in transdermal biosensing and targeted drug deliver. 
Sensors (Basel) 2019;19:1028.
12. Grammatikopoulou MG, Gkiouras K, Dardiotis E, Zafiriou E, 
Tsigalou C, Bogdanos DP. Peeking into the future: Transdermal 
patches for the delivery of micronutrient supplements. Metabol Open 
2021;11:100109.
13. Szunerits S, Boukherroub R. Heat: A highly efficient skin enhancer for 
transdermal drug delivery. Front Bioeng Biotechnol 2018;6:15.
14. Sarveswaran R, Jayasuriya WJ, Suresh TS. In vitro assays to investigate 
the anti-inflammatory activity of herbal extracts: A review. World J 
Pharm Res 2017;6:131-41.
15. Elkoshi Z. The binary classification of chronic diseases. J Inflamm Res 
2019;12:319-33.
16. Nilewar GA, Takdhat PL, Thakre SM, Bhagwatkar PD. Formulation 
and evaluation of repaglinide transdermal patches for treatment of 
diabetes. World J Pharm Res 2018;7:1342-53.
17. Kriplani P, Sharma A, Aman, Pun P, Chopra B, Dhingra A, et al. 
Formulation and Evaluation of Transdermal Patch of Diclofenac 
Sodium. Glob J Pharm Pharm Sci 2018;4:1-4.
18. Saroj AK, Khan R, Sharma B. Transdermal drug delivery system 
(Patch). World J Pharm Res 2019;8:325-43.
19. Cherukuri S, Batchu UR, Mandava K, Cherukuri V, Ganapuram KR. 
Formulation and evaluation of transdermal drug delivery of topiramate. 
Int J Pharm Investig 2017;7:10-7.
20. Mahesh G, Kumar KA, Reddanna P. Overview on the discovery and 
development of anti-inflammatory drugs: Should the focus be on 
synthesis or degradation of PGE2? J Inflamm Res 2021;14:253-63.
21. Kar NR. A review on inflammatory bowel disease- recent pharmaceutical 
approaches to combat it. Int J Pharm Sci Res 2021;12:3593.
22. Saleem S, Muhammad G, Hussain MA, Abbas Bukhari SN. 
A comprehensive review of phytochemical profile, bioactives for 
pharmaceuticals, and pharmacological attributes of Azadirachta indica. 
Phytother Res 2018;32:1241-72.
23. Lalitha P, Sachithanandam V, Swarnakumar NS, Sridhar R. Review on 
anti-inflammatory properties of Mangrove plants. Asian J Pharm Res 
2019;9:273-88.
24. Dasari S, Yedjou CG, Brodell RT, Cruse AR, Tchounwou PB. 
Therapeutic strategies and potential implications of silver nanoparticles 
in the management of skin cancer. Nanotechnol Rev 2020;9:1500-21.
25. Amjadi M, Mostaghaci B, Sitti M. Recent advances in skin penetration 
enhancers for transdermal gene and drug delivery. Curr Gene Ther 
2017;17:139-46.
26. McEvoy L, Carr DF, Pirmohamed M. Pharmacogenomics of 
NSAID-induced upper gastrointestinal toxicity. Front Pharmacol 
2021;12:684162.
27. Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, 
Chaiyakunapruk N. Effects of aspirin and non-aspirin nonsteroidal anti-
inflammatory drugs on the incidence of recurrent colorectal adenomas: 
A systematic review with meta-analysis and trial sequential analysis of 
randomized clinical trials. BMC Cancer 2017;17:763.
28. Rajeswari SR, Gowda T, Kumar T, Mehta DS, Arya K. Analgesic 
efficacy and safety of transdermal and oral diclofenac in postoperative 
pain management following dental implant placement. Gen Dent 
2017;65:69-74.
29. Shinde VA, Kalikar M, Jagtap S, Dakhale GN, Bankar M, Bajait CS, 
et al. Efficacy and safety of oral diclofenac sustained release 
versus transdermal diclofenac patch in chronic musculoskeletal 
pain: A randomized, open label trial. J Pharmacol Pharmacother 
2017;8:166-71.
30. Dasgupta S, Ray S, Dey S, Pal P, Mazumder B. Transdermal lipid 
nanocarriers: A potential delivery system for lornoxicam. Pharm 
Nanotechnol 2017;5:32-43.
31. Palei NN, Mohanta BC, Das MK, Sabapathi ML. Lornoxicam loaded 
nanostructured lipid carriers for top-ical delivery: Optimization, skin 
uptake and in vivo studies. J Drug Deliv Sci Technol 2017;39:490-500.
32. Yu YQ, Yang X, Wu XF, Fan YB. Enhancing permeation of drug 
molecules across the skin via delivery in nanocarriers: Novel strategies 
for effective transdermal applications. Front Bioeng Biotechnol 
2021;9:646554.
33. Ameen D, Michniak-Kohn B. Development and in vitro evaluation 
of pressure sensitive adhesive patch for the transdermal delivery 
of galantamine: Effect of penetration enhancers and crystallization 
inhibition. Eur J Pharm Biopharm 2019;139:262-71.
34. Shivakumar HN, Kotian RS. Design and development of transdermal 
drug delivery of nonsteroidal anti-inflammatory drugs: Lornoxicam 
2019;8:277-83.
35. Yadav AV, Urade MN. Formulation and evaluation of chitosan based 
transdermal patches of lornoxicam for prolonged drug release and to 
study the effect of permeation enhancer. Indian J Pharm Educ Res 
2019;53:88-96.
36. Manickam B, Sreedharan R, Chidambaram K. Drug/vehicle impacts 
and formulation centered stratagems for enhanced transdermal drug 
permeation, controlled release and safety: Unparalleled past and recent 
innovations-an overview. Curr Drug Ther 2019;14:192-209.
37. Puscaselu RG, Lobiuc A, Dimian M, Covasa M. Alginate: From food 
industry to biomedical applications and management of metabolic 
disorders. Polymers 2020;12:2417.
38. Opatha SA, Titapiwatanakun V, Chutoprapat R. Transfersomes: 
A promising nanoencapsulation technique for transdermal drug 
delivery. Pharmaceutics 2020;12:855.
39. Pereira R, Silva SG, Pinheiro M, Reis S, Vale ML. Current status of 
amino acid-based permeation enhancers in transdermal drug delivery. 
Membranes (Basel) 2021;11:343.
40. Ginting E, Reveny J, Sumaiyah. Formulation and evaluation of in vitro 
transdermal patch diclofenac sodium using chitosan polymer and 
polyvinyl alcohol cross linked tripolyphosphate sodium. Asian J Pharm 
Clin Res 2018;11:171-5.
41. Duriya H, Shoaib MH, Ali FR, Siddiqui F. Lornoxicam controlled 
release transdermal gel patch: Design, characterization and optimization 
using co-solvents as penetration enhancer. PLoS One 2020;15:1-23.
42. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. 
Association between insulin resistance and the development of 
cardiovascular disease. Cardiovasc Diabetol 2018;17:122.
43. Wang SL, Dong WB, Dong XL. Comparison of twelve single-drug 
regimens for the treatment of Type 2 diabetes mellitus. Oncotarget 
2017;8:72700-13.
44. Lee YC, Chang CH, Dong YH. Comparing the risks of hospitalized 
heart failure associated with glinide, sulfonylurea, and acarbose use in 
Type 2 diabetes: A nationwide study. Int J Cardiol 2017;228:1007-14.
26
Asian J Pharm Clin Res, Vol 14, Issue 12, 2021, 21-26
 Choudhury et al.
45. Delvecchio M, Pastore C, Giordano P. Treatment options for 
MODY patients: A systematic review of literature. Diabetes Ther 
2020;11:1667-85.
46. Mhatre O, Sodha S. Pharmaceutical feasibility and flow characteristics 
of polymeric non-spherical particles. Nanomedicine 2019;18:243-58.
47. Reddy PS, Bose PS, Sruthi V, Saritha D. Investigation of Kondagogu 
gum to develop transdermal film of repaglinide. Asian J Pharm Clin 
Res 2018;11:440-5.
48. Tian F, Liu T, Xu G, Li D, Ghazi T, Shick T, et al. Adrenergic blockade 
bi-directionally and asymmetrically alters functional brain-heart 
communication and prolongs electrical activities of the brain and heart 
during asphyxic cardiac arrest. Front Physiol 2018;9:99.
49. Trivedi V, Arora N, Arora P. Formulation and evaluation of transdermal 
patches of atenolol. Int J Res Cult Soc 2018;2:13-8.
50. Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G. Absolute 
bioavailability of microdosed midazolam after buccal administration is 
dependent on buccal exposure time. J Clin Pharmacol 2021;61:472-9.
51. Delshadi R, Bahrami A, McClements DJ, Moore MD, Williams L. 
Development of nanoparticle-delivery systems for antiviral agents: 
A review. J Control Release 2021;331:30-44.
52. Ramkanth C, Chetty CM, Sudhakar Y, Thiruvengadarajan VS, Anitha P, 
Gopinath C. Development, characterization and in vivo evaluation of 
proniosomal based transdermal delivery system of atenolol. Future J 
Pharm Sci 2018;4:80-7.
53. Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug 
delivery: Innovative pharmaceutical developments based on disruption 
of the barrier properties of the stratum corneum. Pharmaceutics 
2015;7:438-70.
54. Irvine J, Afrose A, Islam N. Formulation and delivery strategies 
of ibuprofen: Challenges and opportunities. Drug Dev Ind Pharm 
2018;44:173-83.
55. Kelchen MN, Brogden NK. Effect of dosing regimen and microneedle 
pretreatment on in vitro skin retention of topically applied beta-
blockers. Biomed Microdevices 2018;20:100.
56. Mahajan NM, Zode GH, Mahapatra DK, Thakre S, Dumore N, 
Gangane PS. Formulation development and evaluation of transdermal 
patch of piroxicam for treating dysmenorrhoea. J Appl Pharm Sci 
2018;8:35-41.
57. McCrudden MT, Larrañeta E, Clark A, Jarrahian A, ReinWeston A, 
Creelman B, et al. Design, formulation, and evaluation of novel 
dissolving microarray patches containing rilpivirine for intravaginal 
delivery. Adv Healthc Mater 2019;8:1-12.
58. Chime SA, Onunkwo GC, Attama AA. Evaluation of the properties 
of encapsulated stavudine microparticulate lipid-based drug 
delivery system in immunocompromised wistar rats. Curr HIV Res 
2020;18:237-47.
59. Yamsani VV, Mudulaghar MK, Afreen S, Wajid S, Ravula SK, 
Babelghaith SD. Formulation design and in vitro ex vivo evaluation of 
transdermal patches of cinnarizine. Pak J Pharm Sci 2017;30:2075-83.
60. Samal D, Mishra N, Meher B, Kar IB, Kar R, Saipooja RH. Comparison 
of safety, efficacy, patient compliance and cost-effectiveness of 
transdermal, oral and intramuscular diclofenac for pain control following 
oral surgical procedures. J Maxillofac Oral Surg 2021;20:63-9.
61. McNicol ED, Ferguson MC, Schumann R. Single-dose intravenous 
ketorolac for acute postoperative pain in adults. Cochrane Database 
Syst Rev 2021;5:CD013263.
62.	 Kołodziejska	J,	Kołodziejczyk	M.	Diclofenac	in	the	treatment	of	pain	in	
patients with rheumatic diseases. Reumatologia 2018;56:174-83.
63. Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for 
ocular drug delivery: From structural frameworks to recent preclinical 
studies. J Control Release 2017;248:96-116.
64. Jafri I, Shoaib MH, Yousuf RI, Ali FR. Design and evaluation of matrix 
diffusion controlled transdermal patches of verapamil hydrochloride. 
Drug Dev Ind Pharm 2003;29:495-503.
65. Marapur SC, Wali DS, Hunasagi BS, Chetankumar M, Patil RG. 
Formulation and evaluation of transdermal drug delivery system of 
verapamil hydrochloride. J Drug Deliv Ther 2018;8:70-7.
66. Deshpande TM, Quadir A, Obara S, Hoag SW. Impact of formulation 
excipients on the thermal, mechanical, and electrokinetic properties 
of hydroxypropyl methylcellulose acetate succinate (HPMCAS). Int J 
Pharm 2018;542:132-41.
67. Sravanthi K, Reddy DR, Sirisha A, Pavani A, Lakshmi BK, Sowjanya B. 
Preparation and in vitro evaluation of transdermal patch of aceclofenac. 
J Pharmtechnol Res 2020;10:175-81.
68. van Rensburg R, Reuter H. An overview of analgesics: NSAIDs, 
paracetamol, and topical analgesics. S Afr Family Pract 2019;61:S4-10.
69. Akram MR, Ahmad M, Abrar A, Sarfraz RM, Mahmood A. Formulation 
design and development of matrix diffusion controlled transdermal 
drug delivery of glimepiride. Drug Des Dev Ther 2018;12:349-64.
70. Mamatha J, Gadili S, Pallavi K. Formulation and evaluation of 
zidovudine transdermal patch using permeation enhancers. J Young 
Pharm 2020;12 Suppl 2:S45-50.
71. Charoensumran P, Ajiro H. Cationic moieties in polystyrene gels 
swollen with d-limonene improved transdermal delivery system. 
Polymers (Basel) 2018;10:1200.
72.	 Naiserová	M,	 Kubová	 K,	Vysloužil	 J,	 Bernatoniene	 J,	 Brokalakis	 I,	
Vetchý D. (Meth)acrylate copolymers of Eudragit® type in oral tablet 
technology. Ceska Slov Farm 2019;68:183-97.
73. Dutta L, Mukherjee B, Chakraborty T, Das MK, Mondal L, 
Bhattacharya S, et al. Lipid-based nanocarrier efficiently delivers 
highly water soluble drug across the blood-brain barrier into brain. 
Drug Deliv 2018;25:504-16.
74. Bajracharya R, Song JG, Back SY, Han SK. Recent advancements in 
non-invasive formulations for protein drug delivery. Comput Struct 
Biotechnol J 2019;17:1290-308.
75. Ammar HO, Tadros MI, Salama NM, Ghoneim AM. Ethosome-
Derived invasomes as a potential transdermal delivery system for 
vardenafil hydrochloride: Development, Optimization and application 
of physiologically based pharmacokinetic modeling in adults and 
geriatrics. Int J Nanomed 2020;15:5671-85.
76. Tawfik MA, Tadros MI, Mohamed MI, El-Helaly SN. Low-frequency 
versus high-frequency ultrasound-mediated transdermal delivery of 
agomelatine-loaded invasomes: Development, optimization and in-vivo 
pharmacokinetic assessment. Int J Nanomed 2020;15:8893-910.
77. Lundgren M, Steed LJ, Tamura R, Jonsdottir B, Gesualdo P, Crouch C, 
et al. Analgesic antipyretic use among young children in the TEDDY 
study: No association with islet autoimmunity. BMC Pediatr 2017;17:127.
78. Gyöngyösi A, Verner V, Bereczki I, Kiss-Szikszai A, Zilinyi R, 
Tósaki A, et al. Basic pharmacological characterization of EV-34, a 
New H2S-releasing ibuprofen derivative. Molecules 2021;26:599.
79. Jones P, Lamdin R, Dalziel SR. Oral non-steroidal anti-inflammatory 
drugs versus other oral analgesic agents for acute soft tissue injury. 
Cochrane Database Syst Rev 2020;8:CD007789.
80. Coderch L, Collini I, Carrer V, Barba C, Alonso C. Assessment of finite 
and infinite dose in vitro experiments in transdermal drug delivery. 
Pharmaceutics 2021;13:364.
81. Uchida T, Kadhum WR, Kanai S, Todo H, Oshizaka T, Sugibayashi K. 
Prediction of skin permeation by chemical compounds using the 
artificial membrane, Strat-M™. Eur J Pharm Sci 2015;67:113-8.
82. Tombs EL, Nikolaou V, Nurumbetov G, Haddleton DM. Transdermal 
delivery of ibuprofen utilizing a novel solvent-free pressure-sensitive 
adhesive (PSA): TEPI® technology. J Pharm Innov 2018;13:48-57.
